Just read today that analysts who are bullish on R

Just read today that analysts who are bullish on Remdesivir are predicting between $7 billion and $8 billion to Gilead in new annual covid - related revenue in 2022. I believe that is based on an estimated price of $5000 per treatment. These analysts will have to seriously re-calculate those numbers downward when Leronlimab becomes the preferred standard of care a month from now!